Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-560 in Healthy Infants
NCT00508651Phase 2Terminated
- Sponsor
- MedImmune
- Start
- Oct 2007
- Primary completion
- Apr 2009
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of rHPIV3cp45 in human parainfluenza virus type 3 infection (PIV3), sponsored by MedImmune. Started Oct 2007; status: terminated.
02
Drugs
rHPIV3cp45
03
Conditions
human parainfluenza virus type 3 infection (PIV3)
Beyond the preview
Go deeper on NCT00508651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00508651.